Today news
About the same in other media
Polar Capital Healthcare Opportunities breaches 10% exposure limit after Danish pharma firm soars
Reading now: 695
The fund's exposure to Danish pharmaceutical firm Zealand Pharma A/S hit 12.1%, according to its February factsheet, surpassing the 10% limit imposed on UCITS vehicles. Four Graphs explaining silver Zealand Pharma is involved in the production and design of diabetes and obesity medications, a corner of the healthcare market which has seen a huge surge in investment in the wake of Novo Nordisk's Ozempic medication becoming a cult product for weight loss. The company's shares had historically traded at around 200 DKK (£22.92) per share, but last month it experienc...
To continue reading this article...
Join now
Login
Read more on investmentweek.co.ukAbout this in other media
Polar Capital shares surge 16% as strong market gains offset £1.61bn outflows investmentweek.co.uk /2 weeks ago
Can I claim capital gains exemption for consolidating multiple properties into a single residential property? livemint.com /2 weeks ago
Fortis Capital Advisors acquires Chicago-based father-daughter firm investmentnews.com /3 weeks ago
Show more
The website fvbb.com is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.
